Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ISIS-3 final results

Executive Summary

Lancet editorial summarizes results of the comparative study of thrombolysis therapy with Burroughs Wellcome's TPA (duteplase), SmithKline Beecham's APSAC product Eminase or streptokinase by stating that "the clearest message to emerge from this massive enterprise is that both null hypotheses survived intact -- i.e., no thrombolytic regimen performed better, in terms of 35-day survival, than the simple and cheap ISIS-2 cocktail [streptokinase and aspirin]." The final study data are essentially the same as preliminary results from a year ago showing that mortality rates 35 days after myocardial infarction were 10.3% for the TPA group versus 10.6% in the Eminase group and 10.5% for patients receiving streptokinase. The editorial notes that the question of whether TPA was at a disadvantage because concomitant I.V. heparin was not administered should be answered by results of the ongoing 41,000-patient trial GUSTO (Global Utilization of Streptokinase and TPA in Occluded Coronary Arteries). According to Genentech, maker of the TPA product Activase, GUSTO has enrolled 15,000 patients with 500 new patients per week.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel